Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 03.08.2026 FGBL.LN IE00BYTH6121  681,889.00 USD  70,232,837.94  102.997  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 03.08.2026 FKUD IE00BD9N0445  121,463.00 GBP   3,776,407.57   31.091  ...
-

Xtrackers II UK Regulatory Announcement: Important Notice of Dividend Announcement to shareholder of Xtrackers II - Replacement

LONDON--(BUSINESS WIRE)--  Please disregard the Important Notice of Dividend Announcement to shareholder of Xtrackers II announcement released at 09:25 BST on 04 Aug 2026. The full corrected version is shown below. Xtrackers II Investment Company with Variable Capital (société d'investissement à capital variable) Registered office: 17, Boulevard de Kockelscheuer, L-1821 Luxembourg R.C.S. Luxembourg B-124.284 (the “Company”) Important Notice Dividend Announcement 4 August 2026 The Board of Direc...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 03.08.2026 FKU IE00B8X9NZ57  181,700.00 GBP   8,162,267.59   44.922  ...
-

Thryv and Ooma Announce Co-Marketing Agreement Targeting Small Businesses

DALLAS,--(BUSINESS WIRE)--Thryv and Ooma enter a co-marketing agreement, creating new opportunities to introduce their solutions to a broader audience of growth-minded SMBs....
-

Xtrackers II UK Regulatory Announcement: Important Notice of Dividend Announcement to shareholder of Xtrackers II

LONDON--(BUSINESS WIRE)--  Xtrackers II Investment Company with Variable Capital (société d'investissement à capital variable) Registered office: 17, Boulevard de Kockelscheuer, L-1821 Luxembourg R.C.S. Luxembourg B-124.284 (the “Company”) Important Notice Dividend Announcement 4 August 2026 The Board of Directors wishes to inform the Shareholders that a dividend per share for certain Share Classes and Sub-Funds will be paid, as set out below. Please note the following dates which apply to all...
-

Thryv and Wix Announce Intent to Form Strategic Partnership to Power SMB Growth with Unified Commerce, Payments and Website Solutions

DALLAS & NEW YORK--(BUSINESS WIRE)--Thryv and Wix announce plans to establish ​a strategic partnership designed to deliver integrated technology ​solutions to SMBs....
-

NRG Energy Reports Second Quarter 2026 Results and Reaffirms 2026 Financial Guidance

HOUSTON--(BUSINESS WIRE)--NRG Energy, Inc. (NYSE: NRG) today announced financial results for the second quarter ended June 30, 2026, and reports GAAP Net Income of $506 million, GAAP Earnings per Share (EPS) — basic of $2.32, and GAAP Cash Provided by Operating Activities of $1,117 million. The Company's non-GAAP metrics are Adjusted Net Income of $315 million, Adjusted EPS of $1.49, Adjusted EBITDA of $1,217 million, and Free Cash Flow before Growth Investments (FCFbG) of $1,025 million for th...
-

Energy Transfer Reports Second Quarter 2026 Results and Updates 2026 Financial Guidance

DALLAS--(BUSINESS WIRE)--Energy Transfer LP (NYSE:ET) (“Energy Transfer” or the “Partnership”) today reported financial results for the quarter ended June 30, 2026. Energy Transfer reported net income attributable to partners for the three months ended June 30, 2026 of $2.09 billion compared to $1.16 billion for the three months ended June 30, 2025. For the three months ended June 30, 2026, net income per common unit (basic) was $0.59. Adjusted EBITDA for the three months ended June 30, 2026 wa...
-

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. “Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics,” said Anand Parikh, Chief Executive Officer. “...